Tocilizumab Treatment in COVID-19 Patients: Comparing Cutaneous Disease and Adverse Drug Effects.

Publication/Presentation Date

12-1-2023

Abstract

Actemra (tocilizumab) received emergency use authorization for the treatment of coronavirus disease 2019 (COVID-19) in June 2021. Literature has linked numerous cutaneous adverse effects to tocilizumab. In this current survey, investigators reviewed and compared these adverse effects to the common cutaneous manifestations of COVID-19. While similarities in patient presentation exist, important distinctions are made to aid dermatologists in their clinical diagnosis. J Drugs Dermatol. 2023;22(12):e42-e43. doi:10.36849/JDD.6532e.

Volume

22

Issue

12

First Page

42

Last Page

42

ISSN

1545-9616

Disciplines

Medicine and Health Sciences

PubMedID

38051828

Department(s)

Department of Medicine, Department of Medicine Faculty, Department of Medicine Fellows and Residents, Fellows and Residents

Document Type

Article

Share

COinS